Preparation, Optimization and In Vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100

Overview

Journal Pharm Nanotechnol

Specialties Biotechnology
Pharmacology

Date 2019 Mar 21

PMID 30892168

Citations 4

Authors

P Saharan

K Bahmani

S P Saharan

Affiliations

Soon will be listed here.

Abstract

Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media.

Objective: The objective of this study was to develop nanoformulation of glipizide drugloaded nanoparticles providing controlled release formulation.

Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formulation. The effect of key formulation variables on the particle size and entrapment efficiency and drug loading of nanoparticles were studied by using factorial design.

Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and viscosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44 % in 10 hrs at pH 6.8 in phosphate buffer respectively.

Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments.

Citing Articles

Fabrication of glipizide loaded polymeric microparticles; in-vitro and in-vivo evaluation.

Rasheed Q, Ahmad Khan K, Razaque G, Ahmad A, Nawaz A, Akhtar N PLoS One. 2025; 20(1):e0313523.

PMID: 39787127 PMC: 11717267. DOI: 10.1371/journal.pone.0313523.

Computational Amendment of Parenteral In Situ Forming Particulates' Characteristics: Design of Experiment and PBPK Physiological Modeling.

El Hoffy N, Yacoub A, Ghoneim A, Ibrahim M, Ammar H, Eissa N Pharmaceutics. 2023; 15(10).

PMID: 37896273 PMC: 10609842. DOI: 10.3390/pharmaceutics15102513.

Enhanced oral delivery of hesperidin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for augmenting its hypoglycemic activity: in vitro-in vivo assessment study.

Elmoghayer M, Saleh N, Abu Hashim I Drug Deliv Transl Res. 2023; 14(4):895-917.

PMID: 37843733 PMC: 10927856. DOI: 10.1007/s13346-023-01440-6.

Development of a smart pH-responsive nano-polymer drug, 2-methoxy-4-vinylphenol conjugate against the intestinal pathogen, Vibrio cholerae.

Sarveswari H, Gupta K, Durai R, Solomon A Sci Rep. 2023; 13(1):1250.

PMID: 36690664 PMC: 9871008. DOI: 10.1038/s41598-023-28033-0.

Wettability and contact angle affect precorneal retention and pharmacodynamic behavior of microspheres.

Liu H, Han X, Li H, Tao Q, Hu J, Liu S Drug Deliv. 2021; 28(1):2011-2023.

PMID: 34569888 PMC: 8480260. DOI: 10.1080/10717544.2021.1981493.

References

Nayak A, Pal D, Santra K . Ispaghula mucilage-gellan mucoadhesive beads of metformin HCl: development by response surface methodology. Carbohydr Polym. 2014; 107:41-50. DOI: 10.1016/j.carbpol.2014.02.022. View

Hsieh S, Lin J, Cheng H, Ho C, Liou M . Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study. Clin Ther. 2006; 28(9):1318-26. DOI: 10.1016/j.clinthera.2006.09.010. View

Ma Z, Yeoh H, Lim L . Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci. 2002; 91(6):1396-404. DOI: 10.1002/jps.10149. View

Malakar J, Nayak A, Goswami S . Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release. ISRN Pharm. 2013; 2012:730624. PMC: 3529867. DOI: 10.5402/2012/730624. View

Crowley M, Schroeder B, Fredersdorf A, Obara S, Talarico M, Kucera S . Physicochemical properties and mechanism of drug release from ethyl cellulose matrix tablets prepared by direct compression and hot-melt extrusion. Int J Pharm. 2004; 269(2):509-22. DOI: 10.1016/j.ijpharm.2003.09.037. View

Reddy L, Murthy R . Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm. 2004; 54(2):103-18. View

Petkar K, Chavhan S, Kunda N, Saleem I, Somavarapu S, Taylor K . Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design. AAPS PharmSciTech. 2018; 19(4):1758-1772. DOI: 10.1208/s12249-018-0972-9. View

Florence A . Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target. 2004; 12(2):65-70. DOI: 10.1080/10611860410001693706. View

Thombre A, DeNoto A, Gibbes D . Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. J Control Release. 1999; 60(2-3):333-41. DOI: 10.1016/s0168-3659(99)00086-3. View

10.

Ehtezazi T, Washington C, Melia C . First order release rate from porous PLA microspheres with limited exit holes on the exterior surface. J Control Release. 2000; 66(1):27-38. DOI: 10.1016/s0168-3659(99)00255-2. View

11.

Reis C, Neufeld R, Ribeiro A, Veiga F . Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2007; 2(1):8-21. DOI: 10.1016/j.nano.2005.12.003. View

12.

Bera K, Khanam J, Mohanraj K, Mazumder B . Design and evaluation of mucoadhesive beads of glipizide as a controlled release drug delivery system. J Microencapsul. 2013; 31(3):220-9. DOI: 10.3109/02652048.2013.834989. View

13.

Singh B, Bhatowa R, Tripathi C, Kapil R . Developing micro-/nanoparticulate drug delivery systems using "design of experiments". Int J Pharm Investig. 2012; 1(2):75-87. PMC: 3465123. DOI: 10.4103/2230-973X.82395. View

14.

Parikh R, Parikh J, Dubey R, Soni H, Kapadia K . Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS PharmSciTech. 2003; 4(2):E13. PMC: 2750589. DOI: 10.1208/pt040213. View

15.

Patel J, Patel R, Amin A, Patel M . Formulation and evaluation of mucoadhesive glipizide microspheres. AAPS PharmSciTech. 2005; 6(1):E49-55. PMC: 2750411. DOI: 10.1208/pt060110. View

16.

Verma S, Singh S, Verma P . Fabrication of lipidic nanocarriers of loratadine for facilitated intestinal permeation using multivariate design approach. Drug Dev Ind Pharm. 2015; 42(2):288-306. DOI: 10.3109/03639045.2015.1052078. View

17.

Bailey C . Potential new treatments for type 2 diabetes. Trends Pharmacol Sci. 2000; 21(7):259-65. DOI: 10.1016/s0165-6147(00)01506-6. View

18.

Dora C, Singh S, Kumar S, Datusalia A, Deep A . Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm. 2010; 67(3):283-90. View

19.

Verma R, Garg S . Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur J Pharm Biopharm. 2004; 57(3):513-25. DOI: 10.1016/j.ejpb.2004.02.003. View

20.

Khafagy E, Morishita M, Onuki Y, Takayama K . Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007; 59(15):1521-46. DOI: 10.1016/j.addr.2007.08.019. View